^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:ALK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Medicine (Baltimore)
    Title:

    Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

    Published date:
    08/26/2022
    Excerpt:
    The median overall survival was observed 39.2 months. The overall response rate was 66.2%. The ratio of ALK positivity (P = .02), gender (P = .04), and the total number of metastatic sites (P = .02) all were detected as predictors of the response to ALK inhibitor in binary regression analysis....The real-life effectiveness of ALK inhibitors in NSCLC patients with ALK mutations was shown in this research. We determined that having less than 3 metastatic sites, having a high ALK positivity ratio, and being female were all good predictors of ALK inhibitor response.
    DOI:
    10.1097/MD.0000000000030188
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Nat Rev Neurol
    Title:

    Management of brain metastases according to molecular subtypes

    Published date:
    09/01/2020
    Excerpt:
    Several generations of EGFR and ALK inhibitors have shown activity on brain metastases from EGFR and ALK mutant non-small-cell lung cancer.
    DOI:
    10.1038/s41582-020-0391-x